Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

Van de Veire,S., Stalmans,I., Heindryckx,F., Oura,H., Tijeras-Raballand,A., Schmidt,T., Loges,S., Albrecht,I., Jonckx,B., Vinckier,S., Van,S.C., Tugues,S., Rolny,C., De,M.M., Dettori,D., Hainaud,P., Coenegrachts,L., Contreres,J.O., Van,B.T., Cuervo,H., Xiao,W.H., Le,H.C., Buysschaert,I., Kharabi,M.B., Geerts,A., Schomber,T., Bonnin,P., Lambert,V., Haustraete,J., Zacchigna,S., Rakic,J.M., Jimenez,W., Noel,A., Giacca,M., Colle,I., Foidart,J.M., Tobelem,G., Morales-Ruiz,M., Vilar,J., Maxwell,P., Vinores,S.A., Carmeliet,G., Dewerchin,M., Claesson-Welsh,L., Dupuy,E., Van,V.H., Christofori,G., Mazzone,M., Detmar,M., Collen,D., and Carmeliet,P. 2010. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178-190.